greeksoup/ stock research

OptimizeRx Corp.: Q4 FY2025 earnings call

What management said about Q4 FY2025, from the documents filed with the SEC on 5 March 2026: press release. Guidance figures: 1 raised, 1 lowered, 1 new. The quarter’s numbers.

Key takeaways

  • Full-year revenue rose 19%: Full-year revenue was $109.4 million, up from $92.1 million. Fourth-quarter revenue was $32.2 million, consistent with $32.3 million a year earlier. Source
  • Adjusted EBITDA rose for year and quarter: Adjusted EBITDA was $24.3 million for the year, up from $11.7 million. Fourth-quarter adjusted EBITDA was $12.0 million, up from $8.8 million. Source
  • 2026 revenue guidance lowered: Fiscal 2026 revenue is now expected at $109 million to $114 million, down from the $118 million to $124 million introduced in November 2025. Source
  • 2026 adjusted EBITDA guidance raised: Fiscal 2026 adjusted EBITDA is now expected at $21 million to $25 million, up from $19 million to $22 million. Source
  • Operating income positive for year: Full-year income from operations was $11.7 million, against a $13.7 million loss in 2024, which included a $7.5 million impairment charge. Fourth-quarter operating income was $8.6 million. Source
  • Top 20 manufacturers' revenue share fell: Top 20 pharmaceutical manufacturers accounted for 52% of revenue, down from 65%. Average revenue per top 20 manufacturer was $2,838 thousand, down from $2,976 thousand. Source
  • Market volatility rising on MFN pricing: Management said it is beginning to see increased market volatility, linked in part to uncertainty over Most Favored Nation pricing. Source
  • Term loan principal repayments increased: Debt repayments totaled $8.0 million in 2025, up from $4.0 million. Long-term debt, net, was $21.4 million at year end, with $4.3 million current. Source
  • Rule of 40 focus continues: Management said it remains focused on becoming a sustainable Rule of 40 company over the next few years. Source

“For the full year, revenue reached a record $109.4 million and adjusted EBITDA totaled $24.3 million, reflecting more than 20% margin and nearly $19 million in operating cash flow.”

Stephen L. Silvestro, OptimizeRx CEO

Guidance

AreaPeriodFigureAgainst last quarter
Revenue Sourcefiscal year 2026$109 million to $114 millionLowered from $118 million to $124 million
Adjusted EBITDA Sourcefiscal year 2026$21 million to $25 millionRaised from $19 million to $22 million
Share repurchases SourceMarch 12, 2026 to March 15, 2027, or until $10 million is repurchasedup to $10 millionNew

What changed from last quarter

  • Guidance lowered: Fiscal 2026 revenue guidance changed to $109 million to $114 million from $118 million to $124 million. Source
  • Guidance raised: Fiscal 2026 adjusted EBITDA guidance changed to $21 million to $25 million from $19 million to $22 million. Source
  • New: A share repurchase program of up to $10 million was authorized; the prior release did not include one. Source

Full-year and fourth-quarter results

  • Full-year revenue rose 19%: Full-year revenue was $109.4 million, up from $92.1 million. Fourth-quarter revenue was $32.2 million, consistent with $32.3 million a year earlier. Source
  • Adjusted EBITDA rose for year and quarter: Adjusted EBITDA was $24.3 million for the year, up from $11.7 million. Fourth-quarter adjusted EBITDA was $12.0 million, up from $8.8 million. Source
  • GAAP net income positive for year: Full-year GAAP net income was $5.1 million, or $0.27 per diluted share, compared with a net loss of $(20.1) million, or $(1.10) per diluted share, in 2024. Source
  • Non-GAAP net income increased: Full-year non-GAAP net income was $19.9 million, or $1.05 per diluted share, against $6.2 million, or $0.33 per diluted share, in 2024. Source

2026 guidance update

  • 2026 revenue guidance lowered: Fiscal 2026 revenue is now expected at $109 million to $114 million, down from the $118 million to $124 million introduced in November 2025. Source
  • 2026 adjusted EBITDA guidance raised: Fiscal 2026 adjusted EBITDA is now expected at $21 million to $25 million, up from $19 million to $22 million. Source
  • No GAAP reconciliation for guidance: Management said a GAAP reconciliation of forward-looking figures would require unreasonable effort at this time. Source

“In response, we believe some customers are taking a more measured approach to discretionary spending and contract duration.”

Stephen L. Silvestro, OptimizeRx CEO

Costs and margins

  • Fourth-quarter gross profit up 9%: Gross profit was $24.1 million, up from $22.0 million. Fourth-quarter cost of revenues fell to $8.1 million from $10.3 million. Source
  • Full-year cost of revenues rose: Full-year cost of revenues was $35.8 million, up from $32.7 million. Full-year gross profit was $73.6 million, against $59.4 million. Source
  • Operating income positive for year: Full-year income from operations was $11.7 million, against a $13.7 million loss in 2024, which included a $7.5 million impairment charge. Fourth-quarter operating income was $8.6 million. Source
  • Fourth-quarter overhead and stock pay lower: Other general and administrative expenses were $12.1 million, down from $14.4 million. Stock-based compensation was $2.0 million, down from $2.9 million. Source

Customers and key performance indicators

  • Top 20 manufacturers' revenue share fell: Top 20 pharmaceutical manufacturers accounted for 52% of revenue, down from 65%. Average revenue per top 20 manufacturer was $2,838 thousand, down from $2,976 thousand. Source
  • Net revenue retention and staff productivity: Net revenue retention was 116%, down from 121%. Revenue per average full-time employee was $839 thousand, up from $701 thousand. Source
  • Top 20 list updated, prior periods restated: The top 20 definition now uses Fierce Pharma’s ranking by 2024 revenue, previously 2023 revenue. Prior periods were restated for comparison. Source

“While this dynamic may create some near-term headwinds, we continue to see solid engagement across our network and remain confident in the underlying demand trends supporting our business.”

Stephen L. Silvestro, OptimizeRx CEO

Demand and customer spending

  • Market volatility rising on MFN pricing: Management said it is beginning to see increased market volatility, linked in part to uncertainty over Most Favored Nation pricing. Source
  • Near-term headwinds expected: Management said the volatility may create some near-term headwinds for the business. Source
  • Engagement and demand confidence maintained: Management said it continues to see engagement across its network and remains confident in the underlying demand trends. Source

Cash, debt and repayments

  • Cash balance rose to $23.4 million: Cash and cash equivalents were $23.4 million at December 31, 2025, against $13.4 million a year earlier. Source
  • Operating cash flow rose to $18.7 million: Net cash from operating activities was $18.7 million for 2025, against $4.9 million in 2024. Source
  • Term loan principal repayments increased: Debt repayments totaled $8.0 million in 2025, up from $4.0 million. Long-term debt, net, was $21.4 million at year end, with $4.3 million current. Source

Share repurchase program

  • Discretionary program up to $10 million: Repurchases may be made from time to time depending on market conditions, share price, share availability and other factors, at the Company’s discretion. Source
  • Repurchases to be funded from cash: Management intends to finance repurchases using available cash and cash equivalents. Source
  • Board may change or end program: The board may modify, suspend, extend or terminate the program at any time. Source

Strategy and AI positioning

  • Rule of 40 focus continues: Management said it remains focused on becoming a sustainable Rule of 40 company over the next few years. Source
  • AI expected to shift marketing spend: Management expects AI advances to let customers move marketing budgets from content creation toward reach and execution, where it says it offers differentiated value. Source
  • Platform addresses abandonment and interoperability: Management cites reducing script abandonment, improving interoperability between point-of-care platforms, and supporting specialty medications as its role for life sciences companies. Source

Coming up, as management said on 5 March 2026

  • Repurchase authorization takes effect March 12: The $10 million program is effective March 12, 2026 and expires on the earlier of March 15, 2027, or when the $10 million repurchase amount is reached. Source
  • Investor meetings offered: Management said it has set aside time for individual meetings with portfolio managers and analysts, arranged through the listed contacts. Source

Figures management reported

FigureReported
Average revenue per top 20 pharmaceutical manufacturers Source$2,838 thousand (2025) vs $2,976 thousand (2024)
Percent of total revenue attributable to top 20 pharmaceutical manufacturers Source52% (2025) vs 65% (2024)
Net revenue retention Source116% (2025) vs 121% (2024)
Revenue per average full-time employee Source$839 thousand (2025) vs $701 thousand (2024)

Risks management discussed

  • External: Market volatility is rising, linked in part to uncertainty over MFN pricing. Source
  • Demand: Some customers may spend more cautiously on discretionary items and contract length, which management said may create near-term headwinds. Source

Earlier plans management reported on

  • Met: Management said it set a goal to become a Rule of 40 company one year before and achieved the benchmark in 2025. Source
  • Not stated: Fiscal 2025 guidance was raised in the November 2025 release; this 8-K does not state whether full-year results met those ranges.

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.